$25.04 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Vaxcyte

Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Stock Analysis

last close $25.42
1-mo return 2.1%
3-mo return 3.6%
avg daily vol. 270.93T
52-week high 27.22
52-week low 16.78
market cap. $1.6B
forward pe -
annual div. -
roe -41.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 90.4%

Subscribe now for daily local and international financial news